ArticleArchives of microbiology2025
Synergistic antimicrobial effect and mechanism of enterocin Gr17 and cinnamaldehyde against Escherichia coli and Candida albicans.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effect ofPathogens (Basel, Switzerland) · 2026Article
- Inhibitory effects of Quercetagetin on the growth, biofilm formation, and virulence factors of bovine mastitis-associatedFrontiers in microbiology · 2026Article
- Creation of New Antimicrobial Peptides 3: Research Promises and Shortcomings.International journal of molecular sciences · 2025Article
- Antimicrobial effects of essential oil fromFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bacteriocins and essential oils have potential synergistic antimicrobial effects against pathogens, but the poor understanding of their antimicrobial mechanisms, especially against Gram-negative bacteria and fungi, restricts their practical use in public health. Enterocin Gr17 (ENT) is a novel class IIa bacteriocin that exhibits synergistic effects with cinnamaldehyde essential oil (CEO) against some pathogenic Gram-negative bacteria and fungi. This study aimed to further understand the synergistic antimicrobial activity and mechanisms of ENT and CEO against pathogenic Escherichia coli and Candida albicans from the perspectives of cell wall and membrane, morphological structure, respiratory metabolism and gene expression. Results showed that the ENT-CEO combination induced sublethal damage to E. coli and C. albicans, synergistically limiting their growth in a time-dependent manner. For E. coli, ENT and CEO synergistically disrupted the cell wall structure via interfering with membrane potential and targeting cell wall components, then enhanced membrane permeability and formed non-selective pores, leading to K
Indexed as
Identifiers
40643741What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.